Research Use Only
This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.
Tirzepatide
Metabolic & Weight LossFDA ApprovedAlso known as: Tirz, RC-2T, PEP-2T, GIP/GLP, GIP/GLP-1, Dual Agonist
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction at 72 weeks with 15 mg weekly dosing — surpassing semaglutide in head-to-head efficacy comparisons..
Overview
Key Takeaways
- →Superior weight loss
- →Type 2 diabetes
- →Insulin sensitivity
- →Half-life: ~5 days
At A Glance
Tirzepatide is a 39-amino acid synthetic peptide built on a GIP backbone with GLP-1 receptor activity. GIP receptor agonism in adipose tissue enhances lipid storage efficiency and adiponectin release, while GLP-1 receptor agonism drives appetite suppression and insulin secretion. The dual mechanism produces synergistic weight loss effects beyond what either pathway achieves alone. A C20 fatty diacid chain provides albumin binding for a 5-day half-life.
Tirzepatide is a 39-amino acid synthetic peptide built on a GIP backbone with GLP-1 receptor activity. GIP receptor agonism in adipose tissue enhances lipid storage efficiency and adiponectin release, while GLP-1 receptor agonism drives appetite suppression and insulin secretion. The dual mechanism produces synergistic weight loss effects beyond what either pathway achieves alone. A C20 fatty diacid chain provides albumin binding for a 5-day half-life.
Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction at 72 weeks with 15 mg weekly dosing — surpassing semaglutide in head-to-head efficacy comparisons.
Potential Benefits
Potential Research Fields
Chemical Information
IUPAC Name
Not fully specified (proprietary sequence)
CAS Number
2023788-19-2
Molecular Formula
C225H348N48O68
Molecular Mass
4813.49 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Create a free account to:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
Join 2,800+ researchers
Research
Unlock Research Data
Create a free account to:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
Join 2,800+ researchers
Interactions
Interaction Matrix
Contraindications
Personal or family history of MTC. MEN 2 syndrome. History of pancreatitis. Severe GI disease. Pregnancy or breastfeeding.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$84.99
up to $299.99
$4.9998
3
4
vial
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.
Research Score
581 PubMed studies
Quality Indicators
Data Completeness
100%COA Verification
10
Verified COAs
2
Vendors w/ COA
High verification rate (83%)
Latest test: 3/1/2026
Research Credibility
Well-researched compound
Quick Facts
Half-Life
~5 days
Molecular Weight
4813.49 g/mol
Administration
Subcutaneous
CAS Number
2023788-19-2
Trial Phase
FDA Approved
Safety Profile
Moderate RiskCommon Side Effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite
Stop Use If
- Medullary thyroid carcinoma history
- MEN2
- Severe pancreatitis
- Hypersensitivity reaction
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is Tirzepatide used for in research?
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). The SURMOUNT-1 trial demonstrated 20.9% mean body weight reduction at 72 weeks with 15 mg weekly dosing — surpassing semaglutide in head-to-head efficacy comparisons.
What forms does Tirzepatide come in?
Tirzepatide is available in vial form.
How much does Tirzepatide cost?
Prices start at $84.99 across 3 verified vendors.
How do I compare Tirzepatide vendors?
Compare prices, payment methods, shipping, and COA scores across 3 vendors.
Research Tools
Related Compounds
View AllAOD-9604
Metabolic & Weight Loss
AOD-9604 is a modified 16-amino acid fragment of the C-terminal region of human growth hormone (residues 176-191) with an additional tyrosine at the N-terminus and a disulfide bond.
Cagrilintide
Metabolic & Weight Loss
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk.
HGH Fragment 176-191
Metabolic & Weight Loss
HGH Fragment 176-191 is a stabilized peptide fragment of the C-terminus of human growth hormone, corresponding to amino acids 176–191 with a tyrosine addition at the N-terminus.
Retatrutide
Metabolic & Weight Loss
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly targeting GLP-1, GIP, and glucagon receptors simultaneously.
Semaglutide
Metabolic & Weight Loss
Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1.